Effect of Pioglitazone on Ambulatory Blood Pressure
Hypertension, Diabetes Mellitus Type 2
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension
Eligibility Criteria
Inclusion Criteria: Age 45-75 years Diabetes mellitus Type 2 (HbA1c 7 - 8.5%) Casual blood pressure > = 130/80 mmHg, < 160/100 mmHg Exclusion Criteria: Therapy with insulin Combination therapy of sulfonyl-urea und metformin Therapy with nateglinid, repaglinid or an other substance of this drug family Allergy against pioglitazone or other composites of the tablet History of heart failure (NYHA I bis IV) Hepatic insufficiency Transaminases > 2.5-fold of the upper normal limit End-stage renal failure Syndrome of polycystic ovaries Absence of effective contraception in women of childbearing potential Pregnancy or breast-feeding
Sites / Locations
- CRC Medical Department IV
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Pioglitazone
Placebo
Pioglitazone 45 mg, 8 weeks
Placebo